CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 549 enrolled / 549 target
Drug / intervention
Cisplatin +8 moredrug
Likely dose
Cisplatin IV, Cyclophosphamide IV, Lomustine orally, Vincristine Sulfate IV with craniospinal irradiation 18 GyAI-extracted
Key inclusion· 6
  • Histologically confirmed medulloblastoma in posterior fossa with standard-risk disease
  • Minimal residual tumor ≤1.5 cm² on post-operative MRI with contrast within 21 days after surgery
  • No metastatic disease confirmed by spine MRI (within 5 days before or 28 days after surgery) and negative CSF cytology after surgery
  • Brain stem involvement is allowed
Key exclusion· 3
  • Prior chemotherapy
  • Prior radiotherapy
  • Pregnant or nursing females

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00085735
NCT00085735Phase 3CompletedMonitor (2.1/mo)Completion was 123mo ago

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial

Children's Oncology Group·interventional·Posted Jun 16, 2004·Updated Jun 9, 2026

In Brief

A Phase 3 clinical trial evaluating Cisplatin, Craniospinal Irradiation, and 7 other interventions for Medulloblastoma. Completed, enrolled 549 participants across 197 sites in 7 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more effective than reduced-dose radiation therapy when given together with chemotherapy after surgery in treating young patients with medulloblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMedulloblastoma
CountriesAustralia, Canada, Netherlands, New Zealand, Puerto Rico, Switzerland, United States

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 16, 2004
Enrollment StartApr 30, 2004
Primary CompletionMar 31, 2016
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 22.0 years ago

Arms & Interventions

Arm I (3-7 years of age, LDCSI, IFRT)experimental

See Detailed Description (Arm I)

Drug: CisplatinRadiation: Craniospinal IrradiationDrug: CyclophosphamideRadiation: Involved-Field Radiation TherapyOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentDrug: Vincristine Sulfate
Arm II (3-7 years of age, LDCSI, PFRT)experimental

See Detailed Description (Arm II)

Drug: CisplatinRadiation: Craniospinal IrradiationDrug: CyclophosphamideOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: Vincristine Sulfate
Arm III (3-7 years of age, SDCSI, IFRT)experimental

See Detailed Description (Arm III)

Drug: CisplatinRadiation: Craniospinal IrradiationDrug: CyclophosphamideRadiation: Involved-Field Radiation TherapyOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentDrug: Vincristine Sulfate
Arm IV (3-7 years of age, SDCSI, PFRT)active_comparator

See Detailed Description (Arm IV)

Radiation: Craniospinal IrradiationDrug: CyclophosphamideOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: Vincristine Sulfate
Arm V (8-21 years of age, SDCSI, IFRT)experimental

See Detailed Description (Arm V)

Drug: CisplatinRadiation: Craniospinal IrradiationDrug: CyclophosphamideRadiation: Involved-Field Radiation TherapyOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentDrug: Vincristine Sulfate
Arm VI (8-21 years of age, SDCSI, PFRT)active_comparator

See Detailed Description (Arm VI)

Drug: CisplatinRadiation: Craniospinal IrradiationDrug: CyclophosphamideOther: Laboratory Biomarker AnalysisDrug: LomustineOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: Vincristine Sulfate

Interventions

Cisplatindrug

Given IV

Craniospinal Irradiationradiation

Undergo craniospinal Irradiation

Cyclophosphamidedrug

Given IV

Involved-Field Radiation Therapyradiation

Undergo smaller volume boost (involved-field radiation therapy)

Laboratory Biomarker Analysisother

Correlative studies

Lomustinedrug

Given orally

Quality-of-Life Assessmentother

Ancillary studies

Radiation Therapyradiation

Undergo standard volume boost (whole posterior fossa radiation therapy)

Vincristine Sulfatedrug

Given IV